NASDAQ •
Healthcare •
Biotechnology •
Quote as of 08/06/2026 10:33
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization850.8 mln
Float32.94 mln
Earnings Date08/03/2026
Piotroski F-Score
1
/ 9
Very weak
Relative Strength
93
/ 100
Top performer
Debt / Equity
0.01
Debt-free
ROE
-33.87
Deeply negative
Dividend Yield
0.00%
No dividend
DPS
0.00
No dividend
Business Description
Design Therapeutics is a clinical-stage company based in Carlsbad, California, focused on developing small molecule drugs to treat serious genetic diseases caused by abnormal DNA repeat sequences. Using its proprietary GeneTAC platform, the company is advancing treatments for conditions such as Friedreich Ataxia, Myotonic Dystrophy Type 1, Fuchs Endothelial Corneal Dystrophy, and Huntington's Disease ? all of which cause significant damage to the nervous system, muscles, heart, and other vital organs. Founded in 2017, the company aims to address diseases that currently have few or no effective treatment options.
